Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 198-206

  Gregorc, Vanesa ^a   Citterio, Giovanni ^a   Vitali, Giordano ^a   Spreafico, Anna ^a   Scifo, Paola ^a   Borri, Anna ^a   Donadoni, Giovanni ^a   Rossoni, Gilda ^a   Corti, Angelo ^a   Caligaris Cappio, Federico ^a,c   Maschio, Alessandro Del ^a,c   Esposito, Antonio ^a   De Cobelli, Francesco ^a   Dell'Acqua, Flavio ^a   Troysi, Antonella ^d   Bruzzi, Paolo ^b   Lambiase, Antonio ^d   Bordignon, Claudio ^c,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d MOLMED S P A   (Italy)

Author keywords

NGR hTNF; Phase I; Solid tumours

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ASPARAGINYLARGINYLGLYCINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD PRESSURE; CHILL; CLINICAL TRIAL; COLON CANCER; CONTRAST ENHANCEMENT; DIARRHEA; DOSE CALCULATION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MELENA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PAROTITIS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PYELONEPHRITIS; SIDE EFFECT; SOLID TUMOR; VOMITING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71049169690     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.005     Document Type: Article

References (27)

1. Carswell E.A., Old L.J., Kassel R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 72 (1975) 3666-3670
2. Lejeune F.J., Lienard D., Matter M., et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6 (2006) 6
3. Creaven P.J., Brenner D.E., Cowens J.W., et al. A phase I clinical trial of recombinant human tumour necrosis factor given daily for five days. Cancer Chemother Pharmacol 23 (1989) 186-191
4. Gamm H., Lindemann A., Mertelsmann R., et al. Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer 27 (1991) 856-863
5. Kimura K., Taguchi T., Urushizaki I., et al. Phase I study of recombinant human tumour necrosis factor. Cancer Chemother Pharmacol 20 (1987) 223-229
6. Mittelman A., Puccio C., Gafney E., et al. A phase I pharmacokinetic study of recombinant human tumour necrosis factor administered by a 5-day continuous infusion. Invest New Drugs 10 (1992) 183-190
7. Schwartz J.E., Scuderi P., Wiggins C., et al. A phase I trial of recombinant tumour necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1 (1989) 207-214
8. Wiedenmann B., Reichardt P., Rath U., et al. Phase-I trial of intravenous continuous infusion of tumour necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115 (1989) 189-192
9. Eggermont A.M., Schraffordt Koops H., Lienard D., et al. Isolated limb perfusion with high-dose tumour necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14 (1996) 2653-2665
10. Alexander H.R., Brown C.K., Bartlett D.L., et al. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumour necrosis factor-independent mechanisms. Clin Cancer Res 4 (1998) 2357-2362
11. Curnis F., Sacchi A., Borgna L., et al. Enhancement of tumor necrosis factor alpha antitumour immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18 (2000) 1185-1190
12. Corti A., and Ponzoni M. Tumour vascular targeting with tumour necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci 1028 (2004) 104-112
13. Colombo G., Curnis F., De Mori G.M., et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277 (2002) 47891-47897
14. Curnis F., Arrigoni G., Sacchi A., et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumour vessels, epithelia, and myeloid cells. Cancer Res 62 (2002) 867-874
15. Curnis F., Sacchi A., and Corti A. Improving chemotherapeutic drug penetration in tumours by vascular targeting and barrier alteration. J Clin Invest 110 (2002) 475-482
16. van Laarhoven H., Fiedler W., Desar I., et al. Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumours (EORTC 16041). J Clin Oncol 26 (2008) 158s [abstr. 3521]
17. Parker G.J., Suckling J., Tanner S.F., et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7 (1997) 564-574
18. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 (1999) 223-232
19. Collins D.J., and Padhani A.R. Dynamic magnetic resonance imaging of tumour perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 23 (2004) 65-83
20. Cooney M.M., van Heeckeren W., Bhakta S., et al. Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 3 (2006) 682-692
21. Cristofanilli M., Charnsangavej C., and Hortobagyi G.N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov 1 (2002) 415-426
22. Bocci G., Man S., Green S.K., et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 64 (2004) 6616-6625
23. Gaya A.M., and Rustin G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17 (2005) 277-290
24. Fraker D.L., Alexander H.R., and Pass H.I. Biologic therapy with TNF: systemic administration and isolation-perfusion. In: De Vita V., Hellman S., and Rosenberg S. (Eds). Biologic therapy of cancer: principles and practice (1995), JB Lippincott Co., Philadelphia, Pennsylvania 329-345
25. Lienard D., Eggermont A.M., Schraffordt Koops H., et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 4 Suppl. 1 (1994) 21-26
26. Aderka D., Sorkine P., Abu-Abid S., et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. J Clin Invest 101 (1998) 650-659
27. Jackson A., O'Connor J.P.B., Parker G.J.M., et al. Imaging tumour vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13 12 (2007) 3449-3459